New perspectives on the mechanism of methamphetamine-induced neurotoxicity

Japanese Journal of Neuropsychopharmacology

Volumn 28, Issue 2, 2008, Pages 49-61

  Kita, Taizo ^a   Takeshima, Mika ^a   Wagner, George C ^b   Hozumi, Hiroaki ^c   Miyazaki, Ikuko ^c   Asanuma, Masato ^c  

^a KYUSHU NUTRITION WELFARE UNIVERSITY   (Japan)

^b Rutgers University   (United States)

^c OKAYAMA UNIVERSITY   (Japan)

Author keywords

Cytokine; Dopaminequione; Methamphetamine; Neurotoxicity; Self injurious behavior

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; HYDROXYL RADICAL; METHAMPHETAMINE; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ASTROCYTE; AUTOMUTILATION; DOPAMINE RELEASE; DOWN REGULATION; GENE EXPRESSION; MICROGLIA; NEUROTOXICITY; NONHUMAN; REVIEW; SYNAPSE VESICLE; UPREGULATION; WESTERN BLOTTING;

ALPHA-SYNUCLEIN; ANIMALS; ASTROCYTES; CORPUS STRIATUM; CYTOKINES; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FREE RADICALS; HUMANS; INFLAMMATION; METHAMPHETAMINE; MICROGLIA; OXIDATIVE STRESS; SELF-INJURIOUS BEHAVIOR; SUBSTANTIA NIGRA; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 44449131111     PISSN: 13402544     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. Ali, S. F., Newport, G. D., Holson, R. R., Slikker, W. Jr. and Bowyer, J. F. (1994) Low environmental temperatures or pharmacologic agents that produce hypothermia decrease methamphetamine neurotoxicity in mice. Brain Res, 658: 33-38.
2. Asanuma, M. and Cadet, J. L. (1998) Methamphetamine-induced increase in striatal NF-κB DNA-binding activity is attenuated in superoxide dismutase transgenic mice. Mol Brain Res, 60: 305-309.
3. Asanuma, M. and Miyazaki, I. (2006) Nonsteroidal anti-inflammatory drugs in Parkinson's disease: Possible involvement of quinone formation. Expert Rev Neurother, 6: 1313-1325.
4. Asanuma, M., Miyazaki, I. and Ogawa, N. (2003a) Dopamine- or L-DOPA-induced neurotoxicity: The role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox Res, 5: 165-176.
5. Asanuma, M., Tsuji, T., Miyazaki, I., Miyoshi, K. and Ogawa, N. (2003b) Methamphetamine-induced neurotoxicity in mouse brain is attenuated by ketoprofen, a non-steroidal anti-inflammatory drug. Neurosci Lett, 352: 13-16.
6. Asanuma, M., Miyazaki, I., Diaz-Corrales, F.J. and Ogawa, N. (2004a) Quinone formation as dopaminergic neuron-specific oxidative stress in pathogenesis of sporadic Parkinson's disease and neurotoxin-induced parkinsonism. Acta Med Okayama, 58: 221-233.
7. Asanuma, M., Miyazaki, I., Higashi, Y., Tsuji, T. and Ogawa, N. (2004b) Specific gene expression and possible involvement of inflammation in methamphetamine-induced neurotoxicity. Ann NY Acad Sci, 1025: 69-75.
8. Asanuma, M., Miyazaki, I. and Ogawa, N. (2004c) Neuroprotective effects of nonsteroidal anti-inflammatory drugs on neurodegenerative diseases. Curr Pharm Des, 10: 695-700.
9. Axt, K. J., Commins, D. L., Vosmer, G. and Seiden, L. S. (1990) α-Methyl-p-tyrosine pretreatment partially prevents methamphetamine- induced endogenous neurotoxin formation. Brain Res, 515: 269-276.
10. Bauer, M. K., Lieb, K., Schulze-Osthoff, K., Berger, M., Gebicke-Haerter, P. J., Bauer, J. and Fiebich, B. L. (1997) Expression and regulation of cyclooxygenase-2 in rat microglia. Eur J Biochem, 243: 726-731.
11. Boger, H. A., Middaugh, L. D., Patrick, K. S., Ramamoorthy, S., Denehy, E. D., Zhu, H., Pacchioni, A. M., Granholm, A. C. and McGinty, J. F. (2007) Long-term consequences of methamphetamine exposure in young adults are exacerbated in glial cell line-derived neurotrophic factor heterozygous mice. J Neurosci, 27: 8816-8825.
12. Bowyer, J. F., Tank, A. W., Newport, G. D., Slikker, W. Jr., Ali, S. F. and Holson, R. R. (1992) The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum. J Pharmacol Exp Ther, 260: 817-824.
13. Cadet, J. L. and Brannock, C. (1998) Free radicals and the pathobiology of brain dopamine systems. Neurochem Int, 32: 117-131.
14. Cadet, J. L., Sheng, P., Ali, S., Rothman, R., Carlson, E. and Epstein, C. (1994) Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice. J Neurochem, 62: 380-383.
15. Cadet, J. L., Jayanthi, S. and Deng, X. (2003) Speed kills: Cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis. FASEB J, 17: 1775-1788.
16. Choi, H. J., Kim, S. W., Lee, S. Y. and Hwang, O. (2003) Dopamine-dependent cytotoxicity of tetrahydrobiopterin: A possible mechanism for selective neurodegeneration in Parkinson's disease. J Neurochem, 86: 143-152.
17. Choi, H. J., Lee, S. Y., Cho, Y. and Hwang, O. (2005) Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: Relevance to Parkinson's disease. Neurochem Int, 46: 329-335.
18. Cubells, J. F., Rayport, S., Rajendran, G. and Sulzer, D. (1994) Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine- dependent intracellular oxidative stress. J Neurosci, 14: 2260-2271.
19. De Vito, M. J. and Wagner, G. C. (1989) Methamphetamine-induced neuronal damage: A possible role for free radicals. Neuropharmacology, 28: 1145-1150.
20. Du, Z. Y. and Li, X. Y. (1999) Inhibitory effects of indomethacin on interleukin-1 and nitric oxide production in rat microglia in vitro. Int J Immunopharmacol, 21: 219-225.
21. Duffy, S., So, A. and Murphy, T. H. (1998) Activation of endogenous antioxidant defenses in neuronal cells prevents free radical-mediated damage. J Neurochem, 71: 69-77.
22. Eyerman, D. J. and Yamamoto, B. K. (2007) A rapid oxidation and persistent decrease in the vesicular monoamine transporter 2 after methamphetamine. J Neurochem, 103: 1219-1227.
23. Foppoli, C., Coccia, R., Cini, C. and Rosei, M. A. (1997) Catecholamines oxidation by xanthine oxidase. Biochim Biophys Acta, 1334: 200-206.
24. Fornai, F., Lenzi, P., Gesi, M., Soldani, P., Ferrucci, M., Lazzeri, G., Capobianco, L., Battaglia, G., De Blasi, A., Nicoletti, F. and Paparelli, A. (2004) Methamphetamine produces neuronal inclusions in the nigrostriatal system and in PC12 cells. J Neurochem, 88: 114-123.
25. Friedman, S. D., Castaneda, E. and Hodge, G. K. (1998) Long-term monoamine depletion, differential recovery, and subtle behavioral impairment following methamphetamine-induced neurotoxicity. Pharmacol Biochem Behav, 61: 35-44.
26. Fumagalli, F., Gainetdinov, R. R., Valenzano, K. J. and Caron, M. G. (1998) Role of dopamine transporter in methamphetamine-induced neurotoxicity: Evidence from mice lacking the transporter. J Neurosci, 18: 4861-4869.
27. Fumagalli, F., Gainetdinov, R. R., Wang, Y. M., Valenzano, K. J., Miller, G. W. and Caron, M. G. (1999) Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J Neurosci, 19: 2424-2431.
28. Gerlach, M. and Riederer, P. (1996) Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man. J Neural Transm, 103: 987-1041.
29. Giovanni, A., Liang, L. P., Hastings, T. G. and Zigmond, M. J. (1995) Estimating hydroxyl radical content in rat brain using systemic and intraventricular salicylate: Impact of methamphetamine. J Neurochem, 64: 1819-1825.
30. Graham, D. G. (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol, 14: 633-643.
31. Grilli, M., Pizzi, M., Memo, M. and Spano, P. (1996) Neuroprotection by aspirin and sodium salicylate through blockade of NF-κ activation. Science, 274: 1383-1385.
32. Halladay, A. K., Kusnecov, A., Michna, L., Kita, T., Hara, C. and Wagner, G. C. (2003) Relationship between methamphetamine-induced dopamine release, hyperthermia, self-injurious behaviour and long term dopamine depletion in BALB/c and C57BL/6 mice. Pharmacol Toxicol, 93: 33-41.
33. Haque, M. E., Asanuma, M., Higashi, Y., Miyazaki, I., Tanaka, K. and Ogawa, N. (2003) Apoptosis-inducing neurotoxicity of dopamine and its metabolites via reactive quinone generation in neuroblastoma cells. Biochim Biophys Acta, 1619: 39-52.
34. Hara, H., Ohta, M., Ohta, K., Kuno, S. and Adachi, T. (2003) Increase of antioxidative potential by tert-butylhydroquinone protects against cell death associated with 6-hydroxydopamine-induced oxidative stress in neuroblastoma SH-SY5Y cells. Mol Brain Res, 119: 125-131.
35. Hashimoto, K., Nakahara, T., Yamada, H., Hirano, M., Kuroki, T. and Kanba, S. (2007) A neurotoxic dose of methamphetamine induces gene expression of Homer 1a, but not Homer 1b or 1c, in the striatum and nucleus accumbens. Neurochem Int, 51: 227-232.
36. Hastings, T. G. (1995) Enzymatic oxidation of dopamine: The role of prostaglandin H synthase. J Neurochem, 64: 919-924.
37. Hozumi, H., Asanuma, M., Miyazaki, I., Fukuoka, S., Kikkawa, Y., Kimoto, N., Kitamura, Y., Sendo, T., Kita, T. and Gomita, Y. (2008) Protective effects of interferon-gamma against methamphetamine-induced neurotoxicity. Toxicol Lett, 177: 123-129.
38. Imam, S. Z., Newport, G. D., Itzhak, Y., Cadet, J. L., Islam, F., Slikker, W. Jr. and Ali, S. F. (2001) Peroxynitrite plays a role in methamphetamine-induced dopaminergic neurotoxicity: Evidence from mice lacking neuronal nitric oxide synthase gene or overexpressing copper-zinc superoxide dismutase. J Neurochem, 76: 745-749.
39. Itzhak, Y. and Ali, S. F. (1996) The neuronal nitric oxide synthase inhibitor, 7-nitroindazole, protects against methamphetamine-induced neurotoxicity in vivo. J Neurochem, 67: 1770-1773.
40. Itzhak, Y., Martin, J. L., Ali, S. F. and Norenberg, M. D. (1997) Depletion of striatal dopamine transporter does not affect psychostimulant- induced locomotor activity. Neuroreport, 8: 3245-3249.
41. Itzhak, Y., Gandia, C., Huang, P. L. and Ali, S. F. (1998) Resistance of neuronal nitric oxide synthase-deficient mice to methamphetamine-induced dopaminergic neurotoxicity. J Pharmacol Exp Ther, 284: 1040-1047.
42. Jayanthi, S., Deng, X., Ladenheim, B., McCoy, M. T., Cluster, A., Cai, N. S. and Cadet, J. L. (2005) Calcineurin/NFAT-induced up-regulation of the Fas ligand/Fas death pathway is involved in methamphetamine-induced neuronal apoptosis. Proc Natl Acad Sci USA, 102: 868-873.
43. Kadota, T. and Kadota, K. (2004) Neurotoxic morphological changes induced in the medial prefrontal cortex of rats behaviorally sensitized to methamphetamine. Arch Histol Cytol, 67: 241-251.
44. Kawasaki, T., Ishihara, K., Ago, Y., Nakamura, S., Itoh, S., Baba, A. and Matsuda, T. (2006) Protective effect of the radical scavenger edaravone against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum. Eur J Pharmacol, 542: 92-99.
45. Kim, H., Lee, E., Shin, T., Chung, C. and An, N. (1998) Inhibition of the induction of the inducible nitric oxide synthase in murine brain microglial cells by sodium salicylate. Immunology, 95: 389-394.
46. Japanese source
47. Kita, T., Wagner, G. C., Philbert, M. A., King, L. A. and Lowndes, H. E. (1995) Effects of pargyline and pyrogallol on the methamphetamine-induced dopamine depletion. Mol Chem Neuropathol, 24: 31-41.
48. Kita, T., Takahashi, M., Wagner, G. C., Kubo, K. and Nakashima, T. (1998) Methamphetamine-induced changes in activity and water intake during light and dark cycles in rats. Prog Neuropsychopharmacol Biol Psychiatry, 22: 1185-1196.
49. Kita, T., Takahashi, M., Kubo, K., Wagner, G. C. and Nakashima, T. (1999) Hydroxyl radical formation following methamphetamine administration to rats. Pharmacol Toxicol, 85: 133-137.
50. Kita, T., Shimada, K., Mastunari, Y., Wagner, G. C., Kubo, K. and Nakashima, T. (2000a) Methamphetamine-induced striatal dopamine neurotoxicity and cyclooxygenase-2 protein expression in BALB/c mice. Neuropharmacology, 39: 399-406.
51. Kita, T., Matsunari, Y., Saraya, T., Shimada, K., O'Hara, K., Kubo, K., Wagner, G. C. and Nakashima, T. (2000b) Methamphetamine-induced striatal dopamine release, behavior changes and neurotoxicity in BALB/c mice. Int J Dev Neurosci, 18: 521-530.
52. Kita, T., Matsunari, Y., Saraya, T., Shimada, K., O'Hara, K., Kubo, K., Wagner, G. C. and Nakashima, T. (2000c) Evaluation of the effects of α-phenyl-N-tert- butyl nitrone pretreatment on the neurobehavioral effects of methamphetamine. Life Sci, 67: 1559-1571.
53. Kita, T., Wagner, G. C. and Nakashima, T. (2003) Current research on methamphetamine-induced neurotoxicity: Animal models of monoamine disruption. J Pharmacol Sci, 92: 178-195.
54. Koike, K., Hashimoto, K., Fukami, G., Okamura, N., Zhang, L., Ohgake, S., Koizumi, H., Matsuzawa, D., Kawamura, N., Shimizu, E. and Iyo, M. (2005) The immunophilin ligand FK506 protects against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum. Neuropharmacology, 48: 391-397.
55. Japanese source
56. Korytowski, W., Sarna, T., Kalyanaraman, B. and Sealy, R. C. (1987) Tyrosinase-catalyzed oxidation of dopa and related catechol (amine) s: A kinetic electron spin resonance investigation using spin-stabilization and spin label oximetry. Biochim Biophys Acta, 924: 383-392.
57. Kratofil, P. H., Baberg, H. T. and Dimsdale, J. E. (1996) Self-mutilation and severe self-injurious behavior associated with amphetamine psychosis. Gen Hosp Psychiatry, 18: 117-120.
58. Kuhn, D. M., Arthur, R. E. Jr., Thomas, D. M. and Elferink, L. A. (1999) Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: Possible relevance to Parkinson's disease. J Neurochem, 73: 1309-1317.
59. Ladenheim, B., Krasnova, I. N., Deng, X., Oyler, J. M., Polettini, A., Moran, T. H., Huestis, M. A. and Cadet, J. L. (2000) Methamphetamine-induced neurotoxicity is attenuated in transgenic mice with a null mutation for interleukin-6. Mol Pharmacol, 58: 1247-1256.
60. Lai, C. T. and Yu, P. H. (1997) Dopamine- and L-beta-3,4- dihydroxyphenylalanine hydrochloride (L-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and antioxidative factors. Biochem Pharmacol, 53: 363-372.
61. Larsen, K. E., Fon, E. A., Hastings, T. G., Edwards, R. H. and Sulzer, D. (2002) Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J Neurosci, 22: 8951-8960.
62. La Voie, M. J. and Hastings, T. G. (1999) Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: Evidence against a role for extracellular dopamine. J Neurosci, 19: 1484-1491.
63. La Voie, M. J., Card, J. P. and Hastings, T. G. (2004) Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity. Exp Neurol, 187: 47-57.
64. LaVoie, M. J., Ostaszewski, B. L., Weihofen, A., Schlossmacher, M. G. and Selkoe, D. J. (2005) Dopamine covalently modifies and functionally inactivates parkin. Nat Med, 11: 1214-1221.
65. Liao, P. C., Kuo, Y. M., Hsu, H. C., Cherng, C. G. and Yu, L. (2005) Local proteins associated with methamphetamine-induced nigrostriatal dopaminergic neurotoxicity. J Neurochem, 95: 160-168.
66. Liu, Y. and Edwards, R. H. (1997) The role of vesicular transport proteins in synaptic transmission and neural degeneration. Annu Rev Neurosci, 20: 125-156.
67. Lowe, J., McDermott, H., Kenward, N., Landon, M., Mayer, R. J., Bruce, M., McBride, P., Somerville, R. A. and Hope, J. (1990) Ubiquitin conjugate immunoreactivity in the brains of scrapie infected mice. J Pathol, 162: 61-66.
68. Machida, Y., Chiba, T., Takayanagi, A., Tanaka, Y., Asanuma, M., Ogawa, N., Koyama, A., Iwatsubo, T., Ito, S., Jansen, P. H., Shimizu, N., Tanaka, K., Mizuno, Y. and Hattori, N. (2005) Common anti-apoptotic roles of parkin and alpha-synuclein in human dopaminergic cells. Biochem Biophys Res Commun, 332: 233-240.
69. Marek, G. J., Vosmer, G. and Seiden, L. S. (1990) Dopamine uptake inhibitors block long-term neurotoxic effects of methamphetamine upon dopaminergic neurons. Brain Res, 513: 274-279.
70. Mattammal, M. B., Strong, R., Lakshmi, V. M., Chung, H. D. and Stephenson, A. H. (1995) Prostaglandin H synthetase-mediated metabolism of dopamine: Implication for Parkinson's disease. J Neurochem, 64: 1645-1654.
71. 2 and antioxidants have opposite effects on activation of NF-κB and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J, 12: 2005-2015.
72. Miranda, M. and Botti, D. (1983) Harding-passey mouse-melanoma tyrosinase inactivation by reaction products and activation by L-epinephrine. Gen Pharmacol, 14: 231-237.
73. Miyazaki, I., Asanuma, M., Diaz-Corrales, F. J., Fukuda, M., Kitaichi, K., Miyoshi, K. and Ogawa, N. (2006) Methamphetamine-induced dopaminergic neurotoxicity is regulated by quinone formation-related molecules. FASEB J, 20: 571-573.
74. Mori, T., Ito, S., Kita, T. and Sawaguchi, T. (2004) Effects of dopamine- and serotonin-related compounds on methamphetamine-induced self-injurious behavior in mice. J Pharmacol Sci, 96: 459-464.
75. Mori, T., Ito, S., Kita, T., Narita, M., Suzuki, T. and Sawaguchi, T. (2006) Effects of mu-, delta- and kappa-opioid receptor agonists on methamphetamine-induced self-injurious behavior in mice. Eur J Pharmacol, 532: 81-87.
76. Mori, T., Ito, S., Kita, T., Narita, M., Suzuki, T., Matsubayashi, K. and Sawaguchi, T. (2007) Oxidative stress in methamphetamine-induced self-injurious behavior in mice. Behav Pharmacol, 18: 239-249.
77. Munday, R., Smith, B. L. and Munday, C. M. (1998) Effects of butylated hydroxyanisole and dicoumarol on the toxicity of menadione to rats. Chem Biol Interact, 108: 155-170.
78. Murphy, S., Simmons, M. L., Agullo, L., Garcia, A., Feinstein, D. L., Galea, E., Reis, D. J., Mine, G. D. and Schwartz, J. P. (1993) Synthesis of nitric oxide in CNS glial cells. Trends Neurosci, 16: 323-328.
79. Nagai, T., Noda, Y., Ishikawa, K., Miyamoto, Y., Yoshimura, M., Ito, M., Takayanagi, M.,Takuma, K., Yamada, K. and Nabeshima, T. (2005) The role of tissue plasminogen activator in methamphetamine-related reward and sensitization. J Neurochem, 92: 660-667.
80. Nagai, T., Ito, M., Nakamichi, N., Mizoguchi, H., Kamei, H., Fukakusa, A., Nabeshima, T., Takuma, K. and Yamada, K. (2006) The rewards of nicotine: Regulation by tissue plasminogen activator-plasmin system through protease activated receptor-1. J Neurosci, 26: 12374-12383.
81. Nakajima, A., Yamada, K., He, J., Zeng, N., Nitta, A. and Nabeshima, T. (2004) Anatomical substrates for the discriminative stimulus effects of methamphetamine in rats. J Neurochem, 91: 308-317.
82. Narita, M., Akai, H., Nagumo, Y., Sunagawa, N., Hasebe, K., Nagase, H., Kita, T., Hara, C. and Suzuki, T. (2004) Implications of protein kinase C in the nucleus accumbens in the development of sensitization to methamphetamine in rats. Neuroscience, 127: 941-948.
83. Narita, M., Miyatake, M., Shibasaki, M., Tsuda, M., Koizumi, S., Narita, M., Yajima, Y., Inoue, K. and Suzuki, T. (2005a) Long-lasting change in brain dynamics induced by methamphetamine: Enhancement of protein kinase C-dependent astrocytic response and behavioral sensitization. J Neurochem, 93: 1383-1392.
84. Narita, M., Akai, H., Kita, T., Nagumo, Y., Narita, M., Sunagawa, N., Hara, C, Hasebe, K., Nagase, H. and Suzuki, T. (2005b) Involvement of mitogen-stimulated p70-S6 kinase in the development of sensitization to the methamphetamine-induced rewarding effect in rats. Neuroscience, 132: 553-560.
85. Niwa, M, Nitta, A., Yamada, K. and Nabeshima, T. (2007) The roles of glial cell line-derived neurotrophic factor, tumor necrosis factor-alpha, and an inducer of these factors in drug dependence. J Pharmacol Sci, 104: 116-121.
86. O'Callaghan, J. P. and Miller, D. B. (1994) Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther, 270: 741-751.
87. Offen, D., Ziv, L, Sternin, H., Melamed, E. and Hochman, A. (1996) Prevention of dopamine-induced cell death by thiol antioxidants: Possible implications for treatment of Parkinson's disease. Exp Neurol, 141: 32-39.
88. O'Neill, L. A. J. and Kaltschmidt, C. (1997) NF-/cB: A crucial transcription factor for glial and neuronal cell function. Trends Neurosci, 20: 252-258.
89. Pacchioni, A. M., Vallone, J., Melendez, R. L, Shih, A., Murphy, T. H., Kalivas, P. W. (2007) Nrf2 gene deletion fails to alter psychostimulant-induced behavior or neurotoxicity. Brain Res, 1127: 26-35.
90. Ricaurte, G. A., Guillery, R. W., Seiden, L. S., Schuster, C. R. and Moore, R. Y. (1982) Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res, 235: 93-103.
91. Rosei, M. A., Blarzino, C, Foppoli, C, Mosca, L. and Coccia, R. (1994) Lipoxygenase-catalyzed oxidation of catecholamines. Biochem Biophys Res Commun, 200: 344-350.
92. Sato, M. (1992) A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis. Ann NY Acad Sei, 654: 160-170.
93. Japanese source
94. Schlossmacher, M. G., Frosch, M. P., Gai, W. P., Medina, M., Sharma, N., Forno, L., Ochiishi, T., Shimura, H., Sharon, R., Hattori, N., Langsten, J. W., Mizuno, Y., Hyman, B. T., Selkoe, D. J. and Kosik, K. S. (2002) Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol, 160: 1655-1667.
95. Seiden, L. S. and Vosmer, G. (1984) Formation of 6-hydroxydopamine in caudate nucleus of the rat brain after a single large dose of methylamphetamine. Pharmacol Biochem Behav, 21: 29-31.
96. Seiden, L. S. and Ricaurte, G. A. (1987) Neurotoxicity of methamphetamine and related drugs. In Meltzer, H. Y. (ed) Psychopharmacology: The Third Generation of Progress. Raven Press, New York, pp 359-366.
97. Simpson, C. S. and Morris, B. J. (1999) Activation of nuclear factor KappaB by nitric oxide in rat striatal neurones: Differential inhibition of the p50 and p65 subunits by dexamethasone. J Neurochem, 73: 353-361.
98. Sriram, K., Miller, D. B. and O'Callaghan, J. P. (2006) Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: Role of tumor necrosis factor-alpha. J Neurochem, 96: 706-718.
99. Sulzer, D., Bogulavsky, J., Larsen, K. E., Behr, G., Karatekin, E., Kleinman, M. H., Turro, N., Krantz, D., Edwards, R. H., Greene, L. A. and Zecca, L. (2000) Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc Natl Acad Sei USA, 97: 11869-11874.
100. Thomas, D. M., Walker, P. D., Benjamins, J. A., Geddes, T. J. and Kuhn, D. M. (2004) Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J Pharmacol Exp Ther, 311: 1-7.
101. Tief, K., Schmidt, A. and Beermann, F. (1997) Regulation of the tyrosinase promoter in transgenic mice: Expression of a tyrosinaselacZ fusion gene in embryonic and adult brain. Pigment Cell Res, 10: 153-157.
102. Tief, K., Schmidt, A. and Beermann, F. (1998) New evidence for presence of tyrosinase in substantia nigra, forebrain and midbrain. Brain Res Mol Brain Res, 53: 307-310.
103. Tse, D. C, McCreery, R. L. and Adams, R. N. (1976) Potential oxidative pathways of brain catecholamines. J Med Chem, 19: 37-40.
104. Uhl, G. R. (1998) Hypothesis: The role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. Ann Neurol, 43: 555-560.
105. Ujike, H. and Sato, M. (2004) Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Ann NY Acad Sci, 1025: 279-287.
106. Japanese source
107. Wagner, G. C, Ricaurte, G. A., Seiden, L. S., Schuster, C. R., Miller, R. J. and Westley, J. (1980) Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res, 181: 151-160.
108. Wagner, G. C, Lucot, J. B., Schuster, C. R. and Seiden, L. S. (1983) Alpha-methyltyrosine attenuates and reserpine increases methamphetamine-induced neuronal changes. Brain Res, 270: 285-288.
109. Wallace, T. L., Gudelsky, G. A. and Vorhees, C. V. (1999) Methamphetamine- induced neurotoxicity alters locomotor activity, stereotypic behavior, and stimulated dopamine release in the rat. J Neurosci, 19: 9141-9148.
110. Wallace, T. L., Gudelsky, G. A. and Vorhees, C. V. (2001) Neurotoxic regimen of methamphetamine produces evidence of behavioral sensitization in the rat. Synapse, 39: 1-7.
111. Walsh, S. L. and Wagner, G. C. (1992) Motor impairments after methamphetamine-induced neurotoxicity in the rat. J Pharmacol Exp Ther, 263: 617-626.
112. Whitehead, R. E., Ferrer, J. V., Javitch, J. A. and Justice, J. B. (2001) Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter. J Neurochem, 76: 1242-1251.
113. Wrona, M. Z., Yang, Z., Zhang, F. and Dryhurst, G. (1997) Potential new insights into the molecular mechanisms of methamphetamine-induced neurodegeneration. NIDA Res Monogr, 173: 146-174.
114. Xu, Y., Stokes, A. H., Roskoski, R. Jr. and Vrana, K. E. (1998) Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase. J Neurosci Res, 54: 691-697.
115. Yan, Y., Yamada, K., Niwa, M., Nagai, T., Nitta, A. and Nabeshima, T. (2007) Enduring vulnerability to reinstatement of methamphetamine-seeking behavior in glial-cell-line-derived neurotrophic factor mutant mice. FASEB J, 21: 1994-2004.
116. Yu, Q., Zhang, D., Walston, M., Zhang, J., Liu, Y. and Watson, R. R. (2002) Chronic methamphetamine exposure alters immune function in normal and retrovirus-infected mice. Int Immunopharmacol, 2: 951-962.
117. Yuan, J., Callahan, B. T., McCann, U. D. and Ricaurte, G. A. (2001) Evidence against an essential role of endogenous brain dopamine in methamphetamine-induced dopaminergic neurotoxicity. J Neurochem, 77: 1338-1347.
118. Zhang, L., Kitaichi, K., Fujimoto, Y., Nakayama, H., Shimizu, E., Iyo, M. and Hashimoto, K. (2006) Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog Neuropsychopharmacol Biol Psychiatry, 30: 1381-1393.
119. Zhang, X., Dong, F., Mayer, G. E., Bruch, D. C., Ren, J. and Culver, B. (2007) Selective inhibition of cyclooxygenase-2 exacerbates methamphetamine- induced dopamine depletion in the striatum in rats. Neuroscience, 150: 950-958.
120. Zipp, F. and Aktas, O. (2006) The brain as a target of inflammation: Common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci, 29: 518-527.